Overall, this study showed that more than 60% of adult ETP-ALL patients are characterized by a least a single mutation in DNMT3A, FLT3, or NOTCH1 that could guide therapeutic choices in this high-risk subgroup. Here, NOTCH1 is linked to acute lymphoblastic leukemia.